+42.3%
DXCM vs MRNA
+322.6%
-280.4%
-15.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.4% | -3.4% | +5.8% | +2.4% |
| 7D | +4.9% | -12.1% | +17.1% | +5.0% |
| 30D | -0.2% | -1.3% | +1.1% | -0.1% |
| 3M | -8.9% | +250.9% | -259.8% | -8.2% |
| 6M | +42.3% | +343.0% | -300.7% | +46.1% |
| All | +42.3% | +322.6% | -280.4% | +46.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling